R. Akkari

Most-cited papers

1. Decoding Signaling and Function of the Orphan G Protein–Coupled Receptor GPR17 with a Small-Molecule Agonist

   Stephanie Hennen, Hai-Bo Wang, L. Peters, Nicole Merten +19 more

   2013Science Signaling145 citations Open access

   Semantic Scholar

   Save

2. Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs.

   R. Akkari, J. Burbiel, J. Hockemeyer, C. Müller

   2006Current Topics in Medicinal Chemistry75 citations

   Semantic Scholar

   Save

3. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.

   P. Koch, R. Akkari, A. Brunschweiger, T. Borrmann +8 more

   2013Bioorganic & Medicinal Chemistry25 citations Open access

   Semantic Scholar

   Save

4. 3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.

   Younis Baqi, Thanigaimalai Pillaiyar, Aliaa Abdelrahman, Olesja Kaufmann +12 more

   2018Journal of Medicinal Chemistry24 citations Open access

   Semantic Scholar

   Save

5. (R)- or (S)-4-(3-hydroxy-4,4-dimethyl-2-oxopyrrolidin-1-yl)benzoic acid as a new chiral auxiliary for solid phase asymmetric Diels-Alder reactions

   R. Akkari, M. Calmès, F. Escale, Julien Iapichella +2 more

   200420 citations

   Semantic Scholar

   Save

6. Toward Diels−Alder Reactions on a Solid Support Using Polymer Bound N‐Substituted 3‐Hydroxy‐4,4‐dimethyl‐2‐pyrrolidinone Acrylate Derivatives

   R. Akkari, M. Calmès, Jean Martínez

   200412 citations

   Semantic Scholar

   Save

7. Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector

   Mathieu Pizzonero, R. Akkari, Xavier Bock, Romain Gosmini +26 more

   2024Journal of Medicinal Chemistry10 citations Open access

   Semantic Scholar

   Save

8. Abstract 4748: Discovery of JNJ-42756493, a potent fibroblast growth factor receptor (FGFR) inhibitor using a fragment based approach

   P. Angibaud, L. Mevellec, G. Saxty, C. Adelinet +39 more

   201410 citations

   Semantic Scholar

   Save

9. Asymmetric Baylis–Hillman reactions using (R)-4-(3-hydroxy-4,4-dimethyl-2-oxopyrrolidin-1-yl) benzoic acid acrylate derivatives in solution and on solid support

   M. Calmès, R. Akkari, Nicolas P. F. Barthes, F. Escale +1 more

   200510 citations

   Semantic Scholar

   Save

10. (S)-(3-Hydroxy-4,4-dimethyl-2-oxopyrrolidin-1-yl) acetic acid as a solid supported chiral auxiliary in the asymmetric synthesis of β2-homoarylglycines

    R. Akkari, M. Calmès, Delphine Di Malta, F. Escale +1 more

    200310 citations

    Semantic Scholar

    Save

11. Abstract 1361: Fragment based drug discovery of selective inhibitors of Fibroblast Growth Factor Receptor (FGFR)

    G. Saxty, R. Akkari, P. Angibaud, J. Arts +30 more

    20112 citations

    Semantic Scholar

    Save

12. Discovery of GLPG4471, a potent and selective IRAK4 inhibitor for the treatment of inflammatory and autoimmune diseases.

    Oscar Mammoliti, Florence Bonnaterre, Gregory Newsome, R. Akkari +22 more

    2025Bioorganic & Medicinal Chemistry Letters0 citations

    Semantic Scholar

    Save